ResearchMoz

Endotoxemia Global Clinical Trials Review, H1, 2012

Publisher Name » GlobalData
Published Date » 2012-05-21
No. Of Pages » 49


GlobalData's clinical trial report, Endotoxemia Global Clinical Trials Review, H1, 2012" provides data on the Endotoxemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Endotoxemia . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Endotoxemia . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations 
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Keywords

Endotoxemia Clinical Trials, Trial Designs, Subjects Recruited, Unaccomplished Trials of Endotoxemia , Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas, M.D. Andersons, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, National Cancer Center, University of Pennsylvania.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3

Introduction 4
Endotoxemia 4
Report Guidance 4
Clinical Trials by Region 5
Clinical Trials by Country 6
Top Countries Contributing to Clinical Trials in Europe 8
Top Countries Contributing to Clinical Trials in North America 9
Clinical Trials by G7 Nations 10
Clinical Trials in G7 Nations by Trial Status 11
Clinical Trials by Phase 12
In Progress Trials by Phase 13
Clinical Trials by Trial Status 14
Subjects Recruited Over a Period of Time 15
Prominent Sponsors 16
Top Companies Participating in Endotoxemia Therapeutics Clinical Trials 18
Prominent Drug Comparison 19
Clinical Trial Profiles 20
Clinical Trial Overview of Top Companies 20
Green Beat 20
Clinical Trial Overview of Green Beat 20
Spectral Diagnostics Inc. 21
Clinical Trial Overview of Spectral Diagnostics Inc. 21
Danisco A/S 22
Clinical Trial Overview of Danisco A/S 22
Clinical Trial Overview of Top Universities / Institutes / Hospitals 23
Radboud University 23
Clinical Trial Overview of Radboud University 23
Herlev Hospital 24
Clinical Trial Overview of Herlev Hospital 24
Medical University of Vienna 25
Clinical Trial Overview of Medical University of Vienna 25
Rigshospitalet 26
Clinical Trial Overview of Rigshospitalet 26
The University of North Carolina 27
Clinical Trial Overview of The University of North Carolina 27
Five Key Clinical Profiles 28

Appendix 46
Abbreviations 46
Definitions 46
Research Methodology 47
Secondary Research 47
About GlobalData 48
Contact Us 48
Disclaimer 48
Source 49

List of Tables



Endotoxemia Therapeutics Market, Global, Clinical Trials by Zone, 2012* 5
Endotoxemia Therapeutics Market, Global, Clinical Trials by Top Countries, 2012* 6
Endotoxemia Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012* 7
Endotoxemia Therapeutics Clinical Trials, Europe, Top Countries, 2012* 8
Endotoxemia Therapeutics Clinical Trials, North America, Top Countries, 2012* 9
Endotoxemia Therapeutics Clinical Trials, G7 Countries, 2012* 10
Endotoxemia Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012* 11
Endotoxemia Therapeutics Market, Global, Clinical Trials by Phase, 2012* 12
Endotoxemia Therapeutics Market, Global, Clinical Trials In Progress by Phase 2012* 13
Endotoxemia Therapeutics Market, Global, Clinical Trials by Trial Status, 2012* 14
Endotoxemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2005-2010 15
Endotoxemia Therapeutics Clinical Trials, Global, Key Sponsors, 2012* 17
Endotoxemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012* 18
Endotoxemia Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012* 19
Endotoxemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Green Beat, 2012* 20
Endotoxemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Spectral Diagnostics Inc., 2012* 21
Endotoxemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Danisco A/S, 2012* 22
Endotoxemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Radboud University, 2012* 23
Endotoxemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Herlev Hospital, 2012* 24
Endotoxemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2012* 25
Endotoxemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Rigshospitalet, 2012* 26
Endotoxemia Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of North Carolina, 2012* 27

List of Figures

List of Figures

Endotoxemia Therapeutics Market, Global, Clinical Trials by Zone (%), 2012* 5
Endotoxemia Therapeutics Market, Global, Clinical Trials by Top Countries, 2012* 6
Endotoxemia Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012* 7
Endotoxemia Therapeutics Clinical Trials, Europe, Top Countries (%), 2012* 8
Endotoxemia Therapeutics Clinical Trials, North America, Top Countries (%), 2012* 9
Endotoxemia Therapeutics Clinical Trials, G7 Countries (%), 2012* 10
Endotoxemia Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012* 11
Endotoxemia Therapeutics Market, Global, Clinical Trials by Phase (%), 2012* 12
Endotoxemia Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2012* 13
Endotoxemia Therapeutics Market, Global, Clinical Trials by Trial Status, 2012* 14
Endotoxemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2005-2010 15
Endotoxemia Therapeutics Clinical Trials, Global, Key Sponsors, 2012* 16
Endotoxemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012* 18
Endotoxemia Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012* 19
GlobalData Methodology 47

Upcoming Reports:

Luxury Goods Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
The luxury goods market is expected to grow by 7% by the end of 2012 despite the economic slowdown. The major reason behind this significant rise in the luxury goods industry is the rising concern of people over style and personal attire. Changing lifestyle and rising living standards are mainly driving the growth of this market.  China is the leading manufacturer of luxury goods and the predicted growth rate of the Chinese market is about 18% to 20%. The luxury goods industry is forecast to grow between 5% and 7% in America and 2% and 4% in Europe in 2012. Japan, which...
Global Nanosilver Market Analysis and Forecast 2011-201
By - Transparency Market Research
Nanosilver, an emerging technology based market has lot to offer to different markets across industries. Along with all the basic characteristics of the conventional silver, nanosilver is far ahead in offering the additional benefits in various applications such as Nanosilver inks with high conductivity, antibacterial with highly potent antibacterial agents, display as a transparent conductive coating and best alternative to ITO. Investments in Nanosilver technology are luring the inclination worldwide.  Right from its use in scientific application, to medical...
Personal Hygiene Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
The personal hygiene market is growing significantly owing to the increasing interest of people for personal care and health concerns. Many new manufacturers are making their way into the market as a result of the rising trend of personal care products in growing economies.  Personal hygiene is the first step toward good grooming and better health. There are a variety of illnesses that can be prevented just by improving personal hygiene. Some illnesses are not a result of poor personal hygiene, but improving the standards of hygiene will control adverse conditions. ...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012  
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012  
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples. The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012  
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
Battling against flu, vaccination necessary for health workers
Sep 14, 2012  
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease. Health officials...
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012  
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...